Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05838391
Other study ID # AAAU0074
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 18, 2023
Est. completion date December 31, 2028

Study information

Verified date July 2023
Source Columbia University
Contact Mariamne Reyna
Phone 646-317-4244
Email mo2213@cumc.columbia.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a 20 patient pilot study to examine the feasibility of dose-adapted radiation therapy for the treatment of locally advanced anal squamous cell cancer. The tumor and a patient's anatomy may change during radiation treatment and daily adaption of the radiation plan (i.e., a new daily plan based on the anatomy of the day) may help to maximize the dose to the tumor and minimize the radiation dose to the normal surrounding organs.


Description:

The standard treatment for Human Papilloma Virus (HPV)-positive locally advanced anal cancer (described as a tumor that is greater than 4 cm in size, or with positive lymph nodes) is 54 Gy of radiation treatment to the anal canal and primary tumor planning total volume (PTV), 50.4-54 Gy to positive nodal PTV and 45 Gy to elective lymph node PTV with 5-fluorouracil (5-FU) and mitomycin-C chemotherapy administered at the same time as radiation in 30 fraction (treatments) delivery. During the six week course of radiotherapy, there is often a notable decrease in volume of the tumor (both primary and regional nodes), as early as one week into treatment, detected on weekly on-board Cone Beam Computed Tomography (CBCT), which is a scan done on the treatment machine while patients receive radiation to ensure that the tumor is being treated and normal tissue is not. However, CT simulation (a CT scan used to plan radiation treatment) and re-planning of the treatment to account for the tumor shrinkage are not routinely performed due to time, patient inconvenience and staffing resources. As such, daily adaptive radiation, which can generate a new CT-based plan using the anatomy of the day, may be a time efficient method to both plan and treat the patient.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date December 31, 2028
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically proven, invasive primary squamous, basaloid or cloacogenic carcinoma of the anal canal. - American Joint Committee on Cancer (AJCC) 8th edition stage T2 > 4 cm, T3-4 or N1. - Age =18 years. - Eastern Cooperative Oncology Group (ECOG) performance status =2 (Karnofsky =60%). - Life expectancy of greater than 12 months. - Patients must have normal organ and marrow function as defined below: - leukocytes greater than or equal to 3,000/microliter - absolute neutrophil count greater than or equal to 1,500/microliter - platelets greater than or equal to 100,000/microliter - total bilirubin within normal institutional limits - Aspartate transaminase (AST)(SGOT)/Alanine transaminase (ALT)(SGPT) = 2.5 × institutional upper limit of normal - creatinine within normal institutional limits OR creatinine clearance =60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal. - Females of childbearing potential and males must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 6 months after completion of study therapy. All pregnancies must be reported. - Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: - Prior or co-existing invasive malignancy (except non-melanomatous skin cancer) unless disease free = 2 years. - Prior chemotherapy or radiation for anal cancer. - Patients who have undergone complete surgical resection. - Presence of recurrent/metastatic disease. - Prior allergic reaction to 5-Fluorouracil or mitomycin C. - Artificial organ prosthetics, pacemakers or other implantable devices. - Prior radiotherapy to the pelvis that would result in overlap of radiation therapy fields. - Uncontrolled inter-current illness including but not limited to known history of HIV with cluster of differentiation 4 (CD4) count less than 200 or symptomatic cardiac disease. - Women who are pregnant or lactating.

Study Design


Intervention

Radiation:
Artificial Intelligence Guided Daily Radiotherapy Treatment Planning and Delivery
Subjects will receive 54 Gy of radiation delivered 5 day a week for 6 weeks, 30 radiation treatments total. Intensity-Modulated photon radiation therapy will be delivered on a Varian Ethos linear accelerator. Daily image-guided radiation therapy (IGRT) is required. All treatments will have artificial-intelligence (AI) daily adaptations of the radiation plan to optimize the radiation dose to the targeted area and minimize radiation dose to the normal surrounding organs such as the bowel.
Drug:
Mitomycin-C
As part of the subjects' treatment, 10 mg/meters squared of Mitomycin C will be administered intravenously (IV-into the vein) on Day 1 and Day 29.
5-Fluorouracil
As part of the subjects' treatment, 1g/meters squared/day for 4 days of 5-Fluorouracil will be administered by continuous infusion on Days 1-4 (for 96 hours) and Days 29-32 (for 96 hours). 5-Fluorouracil or capecitabine will be administered per the physician's discretion.
Capecitabine
As part of the subjects' treatment, 825 mg/meters squared per day, divided into 2 daily doses, will be taken on days of radiotherapy. Capecitabine or 5-FU will be administered per the physician's discretion.

Locations

Country Name City State
United States Columbia University Irving Medical Center New York New York

Sponsors (2)

Lead Sponsor Collaborator
Columbia University Varian Medical Systems

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to plan and deliver treatment fractions. This is defined by the time the first cone beam computed tomography to the end of treatment delivery for each treatment. Up to 6 weeks
Secondary Acute Treatment Toxicity Toxicity of treatment will be analyzed using NCI-CTCAE v5.0. Up to 1 month post-treatment
Secondary Complete Clinical Response Rate Complete response to treatment (CR) is defined as absence of detectable cancer. 6 months following the completion of chemoradiation
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05060471 - PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients Phase 2
Recruiting NCT06050707 - MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach Phase 2
Completed NCT04616196 - Study of NKTR 255 in Combination With Cetuximab in Solid Tumors Phase 1/Phase 2
Completed NCT01285778 - Vectibix for the Treatment of Anal Cancer Phase 2
Terminated NCT04596033 - TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy Phase 1
Recruiting NCT05374252 - Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients Phase 3
Completed NCT01807546 - Oral Rigosertib for Squamous Cell Carcinoma Phase 2
Recruiting NCT05328765 - A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection
Completed NCT05130073 - 4-Point Therapy Response Score With PET/CT for Anal Squamous Cell Cancer
Recruiting NCT05438836 - Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer
Terminated NCT02407561 - Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression Assays N/A
Completed NCT01115790 - A Phase 1 Study in Participants With Advanced Cancer Phase 1
Recruiting NCT04929028 - Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer Phase 2
Active, not recruiting NCT02560298 - Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer Phase 2
Withdrawn NCT05582031 - Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers Phase 2
Active, not recruiting NCT02437851 - Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection Phase 2